A dose-escalation safety and immunogenicily study of live attenuated oral rotavirus vaccine 116E in Infants: A randomized, double-blind, placebo-controlled trial

Journal of Infectious Diseases

Volumn 200, Issue 3, 2009, Pages 421-429

  Bhandari, Nita ^c   Sharma, Pooja ^b,c   Taneja, Sunita ^c   Kumar, Tivendra ^c   Rongsen Chandola, Temsunaro ^c   Appaiahgari, Mohan Babu ^a,c   Mishra, Arpita ^a,c   Singh, Shakti ^a,c   Vrati, Sudhanshu ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b Independent Consultant   (India)

^c SOCIETY FOR APPLIED STUDIES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; LIVE VACCINE; PLACEBO; ROTAVIRUS VACCINE;

ABDOMINAL DISTENSION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; ROTAVIRUS; ROTAVIRUS 116E; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VERO CELL; VIRUS INFECTION; VIRUS SHEDDING; VIRUS STRAIN; VOMITING;

ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED; VIRUS SHEDDING;

EID: 67650682183     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/600104     Document Type: Article

References (44)

1. The WHO position paper on rotavirus vaccines. Wkly Epidemiol Rec 2007; 82:285-96.
2. Parashar U, Gibson CJ, Bresee JS, Glass Rl. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6.
3. Jain V, Parashar UB, Glass Rl, Bhan MK. Epidemiology of rotavirus in India. Indian J Pediatr 2001;68:855-62.
4. World Health Organization. Report of the meeting on future directions for rotavirus vaccine research in developing countries. Geneva: World Health Organization, 2000.
5. GAVl Alliance. Rotavirus vaccine. Available at: http://www.gavialliance .org/performance/commitments/rotavirus/index.php. Accessed 23 February 2009.
6. Treanor J, Dolin R. Viral infections of the gastrointestinal tract. In: Galasso G, Merigan T, Buchanan RA, eds. Antiviral agents and viral diseases of man. 3rd ed. Philadelphia: Lippincott Raven, 1989:73-414.
7. Vesikari T, Matson DO, Dennehy P, et al. Safety and Efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
8. Ruiz-Palacios GM, Perez-Schael I, Valazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
9. Madhavi Y. Vaccine policy in India. PLoS Medicine 2005;2:el27.
10. Glass RI, Bhan MK, Ray P, et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 2005; 192 (Suppl 1):S30-5.
11. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335: 1022-8.
12. Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis 1994; 169:900-4.
13. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993; 168:282-7.
14. Aiyar J, Bhan MK, Bhandari N, Kumar R, Raj P, Sazawal S. Rotavirusspecific antibody response in saliva of infants with rotavirus diarrhea. J Infect Dis 1990;162:1383-4.
15. Gentsch JR, Das BK, Jiang B, Bhan MK, Glass RI. Similarity of the VP4 protein of human rotavirus strain 116E to that of the bovine B223 strain. Virology 1993; 194:424-30.
16. Das BK, Gentsch JR, Hoshino Y, et al. Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology 1993; 197:99-107.
17. Bhandari N, Sharma P, Glass RI, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and 1321, in infants: results of a randomized controlled trial. Vaccine 2006; 24: 5817-23.
18. World Health Organization child growth standards. Available at: http: //www.who.int/childgrowth/ standards/en/. Accessed 23 February 2009.
19. Nicholson JF, Pesce MA. Reference ranges for laboratory tests and procedures. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. 17th ed. Pennsylvania: Saunders, 2004:2396-427.
20. National Institutes of Health, Division of Microbiology and Infectious Diseases. DMID clinical research policies and standard procedure documents. Available at: http://www3.niaid.nih.gov/research/resources/ DMIDClinRsrch/ toxtables.htm. Accessed 23 February 2009.
21. National Institutes of Health, Division of Microbiology and Infectious Diseases. Good clinical practice handbook. Bethesda, MD: National Institute of Allergy and Infectious Diseases, National Institute of Health, 2001.
22. US Food and Drug Administration. World Medical Association Declaration of Helsinki: recommendations guiding medical doctors in biomedical research involving human subjects. Available at: http://www .fda.gov/oc/health/ helsinki89.html. Accessed 23 February 2009.
23. Indian Council of Medical Research. Ethical guidelines for biomedical research on human participants. Available at: http://www.icmr.nic.in/ ethical-guidelines.pdf. Accessed 23 February 2009.
24. World Health Organization technical report series, no. 878. 1998. Requirement for the use of animal cells as in-vitro substrate for production of biologicals. Available at: http://www.who.int/biologicals/ publications/trs/ areas/vaccines/cells/WHO-TRS-878-AlAnimalcells .pdf. Accessed 23 February 2009.
25. World Health Organization (WHO) Expert Committee on Biological Standardization. WHO technical report series, no. 822. 42nd report. Available at: http://whqlibdoc.who.int/trs/WHO-TRS-822.pdf. Accessed 23 February 2009.
26. World Health Organization technical report series, no. 904.2002. Recommendations for the production and control of poliomyelitis vaccine oral. Available at: http://www.who.int/biologicals/publications/trs/ areas/vaccines/polio/WHO-TRS-904-A1polio-oral.pdf.Accessed Accessed 23 February 2009.
27. World Health Organization Guide to Good Manufacturing Practice Requirements. Part 1: standard operating procedures and master formulae. Available at: http://www.who.int/vaccines-documents/docsPDC/ www.9651.pdf. Accessed 23 February 2009.
28. World Health Organization Guide to Good Manufacturing Practice Requirements. Part 2: validation. Available at: http://www.who.int/ vaccines-documents/DocsPDF/www9666.pdf. Accessed 23 February 2009.
29. Dr. Dang's Medical Diagnostic Centre. Available at: http://www .drdangslab.com/accreditation.asp. Accessed on 23 February 2009.
30. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990;28:276-82.
31. Gentsch J, Glass RI, Woods P, et al. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 1992; 30: 1365-73.
32. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989; 159:79-88.
33. Bines JE, Kohl KS, Forster J, et al. Acute intussuception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis and presentation. Vaccine 2004;22:569-74.
34. Bresee JS, El Arifeen S, Azim T, et al. Safety and immunogenciety of tetravalent rhesus-based rotavirus vaccine in Bangladesh. Pediatr Infect Dis J 2001;20:1136-13.
35. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccine in Bangladeshi infants in a 2- dose schedule at 12 and 16 weeks of weeks of age. Vaccine 2009;27: 1333-9.
36. National Institutes of Health. Assess the immunogenicity and safety of two doses of oral live attenuated human Rota (HRV) vaccine in health infants in India. NCT00289172. Available at: http://clinical trials.gov/ct2/show/ NCT00289172. Accessed 23 February 2009.
37. Ward RL. Mechanisms of protection against rotavirus in humans and mice. J Infect Dis 1996; 174 (Suppl l):S51-8.
38. Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182:1602-9.
39. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of a live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16: 381-7.
40. Madhi SA, Lerumo T, Louw Q et al. Efficacy of human rotavirus vaccine RIX4414 (Rotarix) in South African infants during the first year of life an interim analysis. Available at: http://sabin.org/files/ rota08presentations/ shabir-mahdi-ist.pdf. Accessed 22 November 2008.
41. Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent de-velopments and future considerations. Nat Rev Microbiol 2007; 5: 529-39.
42. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005;24:481-8.
43. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184-90.
44. World Health Organization. Report of the Global Advisory Committee on Vaccine Safety. Wkly Epidemiol Rec 2006;81:13-20.